AP Pharma's drug for chemotherapy-induced nausea denied approval
March 28 (Reuters) - U.S. health regulators denied approval to A.P. Pharma Inc's drug for treating chemotherapy-induced nausea and vomiting, and asked for additional analysis of existing late-stage data on the drug.
The U.S. Food and Drug Administration also asked for a study that can test the usability of the drug's syringe system.
The agency had earlier rejected the approval of the drug, APF530, in March 2010, citing concerns about its two-syringe administration system and deficiencies in the company's contract manufacturing facilities.
A.P. Pharma resubmitted its application in September last year after switching to a single-syringe system and conducting additional metabolism studies as required by the FDA.
- Deadly gun attack in eastern Ukraine shakes fragile Geneva accord |
- Japan expands army footprint for first time in 40 years, risks angering China
- Prosecutors extend Korea ferry captain's detention as death toll mounts |
- Pfizer considers $100 billion bid for AstraZeneca: report
- South Korea recovers first bodies from inside sunken ferry